Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

recruiting4100%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_1

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

NCT06945523
recruitingphase_1

Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

NCT06992583
recruitingphase_1

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma

NCT06903117
recruitingphase_1

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

NCT06768151

Clinical Trials (4)

Showing 4 of 4 trials
NCT06945523Phase 1

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Recruiting
NCT06992583Phase 1

Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

Recruiting
NCT06903117Phase 1

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma

Recruiting
NCT06768151Phase 1

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4